肺吸入制剂的药代动力学评价手段研究进展

doi:10.12092/j.issn.1009-2501.2019.05.018

摘要/Abstract

摘要：

近年来，肺吸入制剂因其在局部治疗及全身治疗中的优越性而受到研究者的广泛关注。完善的评价体系关乎着肺吸入制剂的质量，但目前肺吸入制剂的评价仍侧重于制剂理化性质的鉴定，对药物代谢动力学评价涉及较少，且现有药动学评价手段和方式各异，评价体系尚不完善。本文综述近年来肺吸入制剂的药代动力学评价手段，包括动物药代动力学、酶代谢动力学及细胞药代动力学，以期为后续肺吸入制剂开发过程中的药代动力学评价体系的建设与完善提供思路。

关键词: 肺部给药系统, 吸入制剂, 药代动力学评价

Abstract:

Inhalable formulations have attracted increasing attentions due to the superiority in both local and systemic therapy. Thorough evaluation system is related to the quality of formulations, but the reported papers concerning inhalable formulations mainly focused on the evaluation of physicochemical properties. Pharmacokinetic evaluation is relatively ignored and the evaluation system is unsound. This paper reviews the pharmacokinetic evaluation methods in recent years, including the pharmacokinetic studies in animals, enzymes and cells, to further provide information for the establishment and improvement of pharmacokinetic evaluation system.

Key words: pulmonary delivery system, inhalable formulation, pharmacokinetic evaluation

中图分类号:

R969.1

孔颖，李宁，卢杨，赵娣，任畅，邢晗，陈西敬. 肺吸入制剂的药代动力学评价手段研究进展[J]. 中国临床药理学与治疗学, 2019, 24(5): 595-600.

KONG Ying, LI Ning, LU Yang, ZHAO Di, REN Chang, XING Han, CHEN Xijing. Research progress of pharmacokinetic evaluation methods on inhalable formulations[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 595-600.

参考文献

［1］Nakamura A, Nakajima M, Yamanaka H, et al. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines［J］. Drug Metab Dispos, 2008, 36(8): 1461-1464.
［2］Kuehl PJ, Grimes MJ, Dubose D, et al. Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model ［J］. Drug Deliv, 2018, 25(1): 1127-1136.
［3］Kell SA, Kachura MA, Renn A, et al. Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells ［J］. Int Immunopharmacol, 2019, 66: 296-308.
［4］朱晓婕, 孔颖, 刘琦, 等. 叶酸靶向多西紫杉醇纳米肺吸入粉雾剂的制备及评价［J］. 中国临床药理学与治疗学, 2017, 22(5): 495-500.
［5］He J, Zhang G, Zhang Q, et al. Evaluation of inhaled recombinant human insulin dry powders: pharmacokinetics, pharmacodynamics and 14-day inhalation ［J］. J Pharm Pharmacol, 2019, 71(2): 176-184.
［6］Boger E, Friden M. Physiologically based pharmacokinetic/pharmacodynamic modeling accurately predicts the better bronchodilatory effect of inhaled versus oral salbutamol dosage forms ［J］. J Aerosol Med Pulm Drug Deliv, 2019, 32(1): 1-12.
［7］Patel B, Rashid J, Gupta N, et al. Low-mlecular-weight heparin-coated and montelukast-filled inhalable particles: a dual-drug delivery system for combination therapy in asthma ［J］. J Pharm Sci, 2017, 106(4): 1124-1135.
［8］Gaspar MC, Gregoire N, Sousa JJ, et al. Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres［J］. Eur J Pharm Sci, 2016, 93: 184-191.
［9］Suzuki H, Ueno K, Mizumoto T, et al. Self-micellizing solid dispersion of cyclosporine A for pulmonary delivery: Physicochemical, pharmacokinetic and safety assessments ［J］. Eur J Pharm Sci, 2017, 96: 107-114.
［10］Okuda T, Morishita M, Mizutani K, et al. Development of spray-freeze-dried siRNA/PEI powder for inhalation with high aerosol performance and strong pulmonary gene silencing activity ［J］. J Control Release, 2018, 279: 99-113.
［11］Guilleminault L, Azzopardi N, Arnoult C, et al. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system ［J］. J Control Release, 2014, 196: 344-354.
［12］Rashid J, Alobaida A, Al-Hilal TA, et al. Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH ［J］. J Control Release, 2018, 523(4): 234-244.
［13］Huang Y, Huang Z, Zhang X, et al. Chitosan-based binary dry powder inhaler carrier with nanometer roughness for improving in vitro and in vivo aerosolization performance ［J］. Drug Deliv Transl Re, 2018, 8(5): 1274-1288.
［14］Cuvelier B, Eloy P, Loira-Pastoriza C, et al. Minimal amounts of dipalmitoylphosphatidylcholine improve aerosol performance of spray-dried temocillin powders for inhalation ［J］. Int J Pharm, 2015, 495(2): 981-990.
［15］Geyer A, Lorenzer C, Gehrig S, et al. Fluorescence- and computed tomography for assessing the biodistribution of siRNA after intratracheal application in mice ［J］. Int J Pharm, 2017, 525(2): 359-366.
［16］Shen YB, Du Z, Tang C, et al. Formulation of insulin-loaded N-trimethyl chitosan microparticles with improved efficacy for inhalation by supercritical fluid assisted atomization ［J］. Int J Pharm, 2016, 505(1-2): 223-233.
［17］Scherlieb R, Mnckedieck M, Young K, et al. First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice ［J］. Int J Pharm, 2015, 479(2): 408-415.
［18］Wang Q, Mi G, Hickey D, et al. Azithromycin-loaded respirable microparticles for targeted pulmonary delivery for the treatment of pneumonia ［J］. Biomaterials, 2018, 160: 107-123.
［19］Liao Q, Yip L, Chow MYT, et al. Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition ［J］. Int J Pharm, 2019, 560: 144-154.
［20］Hu Y, Li M, Zhang M, et al. Inhalation treatment of idiopathic pulmonary fibrosis with curcumin large porous microparticles ［J］. Int J Pharm, 2018, 551(1/2): 212-222.
［21］Fu TT, Zhao Y, Yang FF, et al. Ciclesonide and budesonide suspensions for nebulization delivery: An in vivo inhalation biopharmaceutics investigation ［J］. Int J Pharm, 2018, 549(1/2): 21-30.
［22］Eriksson J, Sjogren E, Thorn H, et al. Pulmonary absorption-estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis ［J］. Eur J Pharm Biopharm, 2018, 124: 1-12.
［23］Gupta N, Al-Saikhan FI, Patel B, et al. Fasudil and SOD packaged in peptide-studded-liposomes: Properties, pharmacokinetics and ex-vivo targeting to isolated perfused rat lungs ［J］. Int J Pharm, 2015, 488(1-2): 33-43.
［24］Lu Phuong N, Dang Khoa N, Inthavong K, et al. Particle and inhalation exposure in human and monkey computational airway models ［J］. Inhal Toxicol, 2019: 1-13.
［25］Chen X, Huang W, Wong BC, et al. Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery ［J］. Int J Nanomedicine, 2012, 7: 1139-1148.
［26］Hukkanen J, Pelkonen O, Hakkola J, et al. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung ［J］. Crit Rev Toxicol, 2002, 32(5): 391-411.
［27］Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts ［J］. Annu Rev Pharmacol Toxicol, 2003, 43(1): 149-173.
［28］Dellinger RW, Fang JL, Chen G, et al. Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform ［J］. Drug Metab Dispos, 2006, 34(6): 943-949.
［29］Wei Z, Wanqing L, Federico I, et al. Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms ［J］. PLoS One, 2007, 2(4): e396.
［30］Shan L, Yang S, Zhang G, et al. Comparison of the inhibitory potential of bavachalcone and corylin against UDP-Glucuronosyltransferases ［J］. Evid Based Complement Alternat Med, 2014, 2014: 958937.
［31］Yilmaz Y, Williams G, Walles M, et al. Comparison of rat and human pulmonary metabolism using precision-cut lung slices (PCLS) ［J］. Drug Metab Lett, 2018.
［32］Zhu X, Kong Y, Liu Q, et al. Inhalable dry powder prepared from folic acid-conjugated docetaxel liposomes alters pharmacodynamic and pharmacokinetic properties relevant to lung cancer chemotherapy ［J］. Pulm Pharmacol Ther, 2019, 55:50-61.
［33］Patel B, Rashid J, Ahsan F. Aerosolizable modified-release particles of montelukast improve retention and availability of the drug in the lungs ［J］. Eur J Pharm Sci, 2017, 96: 560-570.
［34］Alimbetov D, Askarova S, Umbayev B, et al. Pharmacological targeting of cell cycle, apoptotic and cell adhesion signaling pathways implicated in chemoresistance of cancer cells ［J］. Int J Mol Sci, 2018, 19(6): 1690.
［35］Elgohary MM, Helmy MW, Abdelfattah EA, et al. Targeting sialic acid residues on lung cancer cells by inhalable boronic acid-decorated albumin nanocomposites for combined chemo/herbal therapy ［J］. J Control Release, 2018, 285: 230-243.
［36］Rosière R, Woensel MV, Mathieu V, et al. Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy ［J］. Int J Pharm, 2016, 501(1/2): 148-159.
［37］Jyoti K, Kaur K, Pandey RS, et al. Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies ［J］. J Colloid Interf Sci, 2015, 445: 219-230.
［38］Foster KA, Avery ML, Yazdanian M, et al. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery ［J］. Int J Pharm, 2000, 208(1): 1-11.
［39］Xin OH, Daniela T, Young PM. Pharmaceutical applications of the Calu-3 lung epithelia cell line ［J］. Expert Opin Drug Deliv, 2013, 10(9): 1287-1302.
［40］Suzuki EY, Amaro MI, de Almeida GS, et al. Development of a new formulation of roflumilast for pulmonary drug delivery to treat inflammatory lung conditions ［J］. Int J Pharm, 2018, 550(1/2): 89-99.
［41］Salar-Behzadi S, Wu S, Mercuri A, et al. Effect of the pulmonary deposition and in vitro permeability on the prediction of plasma levels of inhaled budesonide formulation ［J］. Int J Pharm, 2017, 532(1): 337-344.
［42］Rigo LA, Carvalho-Wodarz CS, Pohlmann AR, et al. Nanoencapsulation of a glucocorticoid improves barrier function and anti-inflammatory effect on monolayers of pulmonary epithelial cell lines ［J］. Eur J Pharm Biopharm, 2017, 119: 1-10.
［43］Patel B, Gupta N, Ahsan F. Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome ［J］. Eur J Pharm Biopharm, 2015, 89: 163-174.
［44］陆亚媛, 赵娣, 李宁, 等. 缓释型肺吸入制剂的研究进展［J］. 药学研究, 2018, 37(8): 469-472,481.
［45］van Rijt SH, Bolukbas DA, Argyo C, et al. Applicability of avidin protein coated mesoporous silica nanoparticles as drug carriers in the lung ［J］. Nanoscale, 2016, 8(15): 8058-8069.
［46］Rashid J, Patel B, Nozik-Grayck E, et al. Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH) ［J］. J Control Release, 2017, 250: 96-106.

[1]	刘敏, 孔祥, 章叶, 顾逸飞, 项雪梅, 贺晴, 黄凯. 经口吸入制剂临床试验健康受试者筛选失败原因分析[J]. 中国临床药理学与治疗学, 2023, 28(7): 758-766.
[2]	刘敏, 孔祥, 章叶, 顾逸飞, 项雪梅, 黄凯. 经口吸入制剂在中国健康受试者生物等效性试验中的安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(10): 1131-1138.
[3]	顾逸飞, 储楠楠, 黄凯, 阙琳玲, 张继胜, 项雪梅, 贺晴. 药效动力学研究在经口吸入制剂生物等效性评价中的应用进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 822-833.
[4]	朱丽丽, 朱秀秀, 王文俊, 张海邻, 林立. 国内儿科人群吸入制剂药物临床试验现状分析[J]. 中国临床药理学与治疗学, 2022, 27(2): 178-183.
[5]	张继胜, 黄凯, 储楠楠, 贺晴. 药代动力学研究在经口吸入制剂生物等效性评价中的应用进展[J]. 中国临床药理学与治疗学, 2020, 25(11): 1295-1308.